Skip to Main Content

Paper Details

Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.
JNCI Cancer Spectr
4
2022
Author NameAffiliation
Sebastian SchneeweissDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School
Sebastian SchneeweissHarvard T.H. Chan School of Public Health
Shirley V WangDivision of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School
  • 1 - 3

Datasets